Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21789862> ?p ?o }
Showing triples 1 to 25 of
25
with 100 triples per page.
- Q21789862 subject Q8300826.
- Q21789862 subject Q9052781.
- Q21789862 wikiPageWikiLink Q1367466.
- Q21789862 wikiPageWikiLink Q159236.
- Q21789862 wikiPageWikiLink Q19882011.
- Q21789862 wikiPageWikiLink Q204711.
- Q21789862 wikiPageWikiLink Q204727.
- Q21789862 wikiPageWikiLink Q211675.
- Q21789862 wikiPageWikiLink Q5059596.
- Q21789862 wikiPageWikiLink Q5059912.
- Q21789862 wikiPageWikiLink Q6710274.
- Q21789862 wikiPageWikiLink Q6710283.
- Q21789862 wikiPageWikiLink Q7180990.
- Q21789862 wikiPageWikiLink Q780.
- Q21789862 wikiPageWikiLink Q796758.
- Q21789862 wikiPageWikiLink Q8047.
- Q21789862 wikiPageWikiLink Q8300826.
- Q21789862 wikiPageWikiLink Q9052781.
- Q21789862 type ChemicalSubstance.
- Q21789862 type Drug.
- Q21789862 type ChemicalObject.
- Q21789862 type Thing.
- Q21789862 type Q8386.
- Q21789862 comment "Sebelipase alfa is a recombinant form of the enzyme lysosomal acid lipase (LAL) that was approved in 2015 under the tradename Kanuma in the US and EU for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).Sebelipase was developed by Synageva that became part of Alexion Pharmaceuticals in 2015. For its production chicken are genetically modified to produce the recombinant form of LAL (rhLAL) in their egg white.".
- Q21789862 label "Sebelipase alfa".